Press Releases April 30, 2026 04:00 PM

Mdxhealth to Release First Quarter 2026 Financial Results on May 13

Mdxhealth Announces Q1 2026 Financial Results Release and Conference Call on May 13

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
MDXH

Mdxhealth SA, a precision diagnostics company, will release its Q1 2026 financial results on May 13, 2026, after market close and host a live conference call and webcast with Q&A. The company focuses on molecular diagnostics for prostate cancer and other urologic diseases using proprietary genomic and molecular technologies.

Mdxhealth to Release First Quarter 2026 Financial Results on May 13
MDXH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Mdxhealth to release Q1 2026 financial results on May 13 after market close.
  • Company will hold a conference call and webcast with live Q&A at 4:30pm ET on May 13.
  • Mdxhealth specializes in precision diagnostics for prostate cancer and urologic diseases using advanced molecular technologies.

Mdxhealth to Release First Quarter 2026 Financial Results on May 13

Company to Host Conference Call with Live Q&A, May 13, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – April 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2026, after market close on Wednesday, May 13, 2026.

Title:

Mdxhealth Presents First Quarter 2026 Financial Results and
Corporate Update Conference Call and WebcastDate:May 13, 2026Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:

United States: 1-800-245-3047
Belgium: 0800 72 519
United Kingdom: 0808 101 1183



Conference ID:        MDX1Q26Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1758088&tp_key=21da6e9d38

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

info@mdxhealth.com

LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
jfraunces@lifesciadvisors.com

Attachment

  • MDXH 1Q26 Earnings Save the Date (May13)

Risks

  • Financial results may not meet market expectations, potentially impacting stock price.
  • Market adoption of Mdxhealth's diagnostic tests depends on physician acceptance and healthcare sector reimbursement policies.
  • Competition in the precision diagnostics and molecular testing market could affect Mdxhealth's growth prospects.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026